| A convenient examination such as blood tests that can evaluate the progression to dementia or cognitive decline in population at-risk is urgently needed. |
| The results of reported plasma biomarkers relevant to Alzheimer’s disease, such as Aβ1–40, Aβ1–42 and Tau, in patients with Down syndrome, stroke and amnestic mild cognitive impairment are discussed |
| The levels of plasma Aβ1–42 are possibly the most dominant to predict the cognitive decline in these patients. |
| It would be hopeful to stop the development of dementia or delay cognitive decline by eliminating the abnormal changes in the level of plasma Aβ1–42. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.